Last reviewed · How we verify
TDT067 and Lamisil
At a glance
| Generic name | TDT067 and Lamisil |
|---|---|
| Also known as | Lamisil |
| Sponsor | Celtic Pharma Development Services |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails (PHASE2)
- Efficacy Comparison of Itraconazole Pulse Therapy and Terbinafine Therapy in Treatment of Tinea Capitis in Children. (NA)
- Efficacy of Ultraviolet B Phototherapy in the Management of Resistant and Relapsing Tinea Corporis and Tinea Cruris (NA)
- Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine (NA)
- Terbinafine Hydrochloride for the Treatment of Otomycosis (NA)
- From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients (PHASE1, PHASE2)
- A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) (PHASE3)
- Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDT067 and Lamisil CI brief — competitive landscape report
- TDT067 and Lamisil updates RSS · CI watch RSS
- Celtic Pharma Development Services portfolio CI